UX-GIP001

Phase 1Biologic

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

UX-GIP001 is one of 49 biologic programs targeting Temporal Lobe Epilepsy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Temporal Lobe EpilepsyNot yet recruiting

EpilepsyRecruiting

Temporal Lobe EpilepsyPhase 1

Not yet recruiting

EpilepsyPhase 1

Recruiting

Competition

Competitive Landscape

87 competitors in Epilepsy

#DrugCompanyPhaseTrials

Vimpat

UCB

Approved

11 2

Tegretol

Novartis

Approved

11 3

Trileptal

Novartis

Approved

7 4

Fycompa

CCatalyst Biosciences

Approved

14 5

Lexapro

AbbVie

Approved

2 6

Briviact

UCB

Phase 3

15 7

Dilantin

VViatris Specialty LLC

Approved

3 8

Epidiolex

Jazz Pharmaceuticals

Phase 3

9 9

Ketalar

AAultman Health Foundation

Approved

1 10

Coumadin

AAbbott

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Temporal Lobe Epilepsy

NCT07244328

Q3 2029

Phase 1Recruiting

Epilepsy

NCT07572812

Clinical

Trials by Indication[1]

Temporal Lobe Epilepsy1 trial

Exploratory Study of UX-GIP001 Cell Therapy in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07244328·6 enrolled

Epilepsy1 trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of UX-GIP001 (Human GABAergic Interneuron Progenitor Cells Injection) in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting·SShanghai UniXell Biotechnology Co., Ltd·Phase 1·NCT07572812·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for UX-GIP001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UX-GIP001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UX-GIP001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

UX-GIP001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

Temporal Lobe Epilepsy1 trial

Epilepsy1 trial

References

Drug Info

Quick Facts

Related News